Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis

**Study Purpose:** This is a Phase Ib/Ila study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis.

**Recruitment Information:**

**Study Type:** Phase Ib/Ila, open-label, interventional study.

**Status:** Recruiting

**Target Patient:** Patients with treatment – resistant, generalized Myasthenia Gravis

**Eligible Ages:** 18 years and older

*Link to appropriate websites* [https://www.cartesiantherapeutics.com/descartes-08-generalized-myasthenia-gravis/](https://www.cartesiantherapeutics.com/descartes-08-generalized-myasthenia-gravis/)


**Inclusion and Exclusion Criteria:**

**Inclusion Criteria:** MGFA Grade 3 or 4; Must have Positive Acetylcholine Receptor or MuSK Antibodies. Failed treatment with 2 immunosuppressive drugs for at least one year, or failed 1 immunosuppressive drug for at least one year and requiring repetitive IVIG / Plasma Exchange

**Exclusion Criteria:** Other major chronic illness that may increase the risk to the patient. Other inclusion and exclusion criteria apply. Please contact study sites.

**Study Information:**

**Sponsor:** Cartesian Therapeutics, Inc.
Principal Investigator: Volkan Granit, MD

Study Coordinator: Study Trial Central Contact, 302-648-6497

Type of Study: Phase Ib/Ila, open-label, interventional study.

Study Duration: 18 months

Single Center/Multi-center: Multi-Center

Travel Funds Available: ☒ Y ☐ N

Find A Center Near You:

List Sites Here

Additional Sites are being added. For a current list of clinical trial sites, please visit: https://clinicaltrials.gov/ct2/show/NCT04146051

Site: University of Miami, Miller School of Medicine

PI: Volkan Granit, MD, MSc

Coordinator: Maria Elena Paredes - mep132@med.miami.edu

Site: University of California, Irvine

PI: Tahseen Mozaffar, MD

Coordinator: Julia Fong juliakf@hs.uci.edu